Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of the proposed study is to characterize the oxidative stress and inflammatory cytokine status in UCD during baseline and decompensated states.
| Condition |
|---|
|
Urea Cycle Disorders |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders |
- Laboratory values indicating oxidative stress [ Time Frame: Change from baseline to period of decompensation up to one year ] [ Designated as safety issue: No ]Laboratory values that indicate oxidative stress include IL-1, IL-2, IL-6, and IL-8. These values will be analyzed as a panel (not individually) comparing baseline values to values during periods of decompensation.
| Estimated Enrollment: | 50 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | July 2014 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
Protein turnover is a cyclic process with a net loss of protein in the fasting state and a net gain in the fed state contributing to nitrogen balance. These physiologic processes are impacted during infection; whole-body protein catabolism exceeds protein synthesis, resulting in net loss of whole-body protein. Patients with urea cycle disorders suffer episodes of periodic hyperammonemic crisis, often in association with intercurrent infections. The immediate cause of this decompensation is the increase in endogenous protein catabolism that is the endpoint of a cascade triggered by intercurrent illness. This increase in protein catabolism leads to elevations of serum amino acids and ammonia production, which cannot be eliminated by a dysfunctional urea cycle.
It is well known that infectious illnesses play a significant role in precipitating metabolic crises in urea cycle defects, presumably by triggering a cascade of events involving the release of inflammatory cytokines that lead to increased protein catabolism. Cytokines have also been implicated as distant mediators of oxidative stress. However, the correlation between oxidative stress, cytokine levels, and severity of a crisis is currently unclear.
The primary purpose of the proposed study is to characterize the oxidative stress and inflammatory cytokine status in UCD during baseline and decompensated states. The investigators will undertake measurements of selected markers of oxidative stress and cytokines in serum and urine during baseline and decompensated states in subjects with UCD in order to establish their prognostic value as biomarkers for disease severity and/or predictors of metabolic decompensation.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Urea cycle disorders Inherited metabolic disorders N-acetylglutamate synthase (NAGS) deficiency Carbamyl phosphate synthetase I (CPSI) deficiency Ornithine transcarbamylase (OTC) deficiency Argininosuccinate synthetase (AS) deficiency (Citrullinemia) Argininosuccinate lyase (AL) deficiency (argininosuccinic aciduria Arginase (ARG) deficiency (hyperargininemia) Hyperornithinemia, hyperammonemia and homocitrullinuria (HHH) syndrome, or mitochondrial ornithine carrier (ORNT) deficiency Citrullinemia type II, mitochondrial aspartate/glutamate carrier (CITR) deficiency
Inclusion Criteria:
- Confirmed or highly-likely diagnosis of one of the eight UCDs as established for the Longitudinal Study (5101) (See section 4.2 Inclusion Criteria, Table 4 for diagnostic criteria for patients with UCD)
- Enrolled in Longitudinal Study of Urea Cycle Disorders (RDCRN UCDC #5101)
Exclusion Criteria:
- UCD patients who have undergone orthotopic liver transplantation
- Significant chronic medical co-morbidity that might confound the analysis as determined by the site investigators.
Significant co-morbidities include but are not limited to:
- diabetes, liver failure + cirrhosis
- renal failure
- cardiac disease
- chronic inflammatory diseases
- asthma requiring daily long-term control medications
- significant respiratory disease.
Contacts and Locations| Contact: Nina Schrager | 212-241-6805 | nina.schrager@mssm.edu |
| United States, California | |
| University of California, Los Angeles | Recruiting |
| Los Angeles, California, United States, 90095 | |
| Contact: Naghmeh Dorrani, MS, CGC 310-825-8084 Ndorrani@mednet.ucla.edu | |
| Sub-Investigator: Stephen Cederbaum, MD | |
| Principal Investigator: Derek Wong, MD | |
| United States, Colorado | |
| The Children's Hospital, Aurora | Not yet recruiting |
| Aurora, Colorado, United States, 80045 | |
| Contact: Curtis Coughlin, MS, CGC 303-724-2310 Coughlin.Curtis@tchden.org | |
| Principal Investigator: Renata C. Gallagher, MD, PhD | |
| United States, District of Columbia | |
| Children's National Medical Center | Recruiting |
| Washington, District of Columbia, United States, 20010 | |
| Contact: Kara Simpson, MS, CGC 202-476-6216 ksimpson@childrensnational.org | |
| Principal Investigator: Uta Lichter-Konecki, MD, PhD | |
| United States, Minnesota | |
| University of Minnesota | Not yet recruiting |
| Minneapolis, Minnesota, United States, 55455 | |
| Contact: Susan Berry, MD berry002@umn.edu | |
| Contact: Sara Elsbecker, MS, RN, CPNP 612-626-5275 selsbeck10@umphysicians.umn.edu | |
| Principal Investigator: Susan Berry, MD | |
| United States, New York | |
| Mount Sinai School of Medicine | Recruiting |
| New York, New York, United States, 10029 | |
| Contact: Nina Schrager 212-241-6805 nina.schrager@mssm.edu | |
| Principal Investigator: George A. Diaz, MD | |
| United States, Ohio | |
| Case Western Medical College | Not yet recruiting |
| Cleveland, Ohio, United States, 44106 | |
| Contact: Christine Heggie, BSN, ND 216-844-7124 Christine.Heggie@UHhospitals.org | |
| Principal Investigator: Douglas Kerr, MD | |
| Sub-Investigator: Shawn McCandless, MD | |
| United States, Oregon | |
| Oregon Health and Science University | Not yet recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Tina Marrone 503-418-3620 marronet@ohsu.edu | |
| Principal Investigator: Cary Harding, MD | |
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | Not yet recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Contact: Irma Payan, RN 215-590-6236 Payan@email.chop.edu | |
| Principal Investigator: Marc Yudkoff, MD | |
| United States, Texas | |
| Baylor College of Medicine | Not yet recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Mary Mullins, RN, BSN 832-822-4263 mullins@bcm.edu | |
| Principal Investigator: Brendan Lee, MD, PhD | |
| United States, Washington | |
| Children's Hospital and Regional Medical Center | Not yet recruiting |
| Seattle, Washington, United States, 98105 | |
| Contact: Linnea Brody, BS, MPH 206-987-3694 linnea.brody@seattlechildrens.org | |
| Principal Investigator: Lawrence Merritt, MD | |
| Canada, Ontario | |
| The Hospital for Sick Children | Recruiting |
| Toronto, Ontario, Canada, M5G 1X8 | |
| Contact: Munazzah Ambreen 416-813-7654 ext 2646 munazzah.ambreen@sickkids.ca | |
| Sub-Investigator: Annette Feigenbaum, MD | |
| Principal Investigator: Andreas Schulze, MD | |
| Principal Investigator: | George Diaz, MD | Mount Sinai School of Medicine |
More Information
Additional Information:
No publications provided
| Responsible Party: | Children's Research Institute |
| ClinicalTrials.gov Identifier: | NCT01541722 History of Changes |
| Other Study ID Numbers: | RDCRN 5109, U54HD061221 |
| Study First Received: | February 8, 2012 |
| Last Updated: | April 15, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Children's Research Institute:
|
Urea cycle disorders |
Additional relevant MeSH terms:
|
Inflammation Urea Cycle Disorders, Inborn Pathologic Processes Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Amino Acid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013